Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics is maintaining a 'Buy' rating following a significant $2.65 billion sale of its muscular dystrophy program to Servier. The company plans to utilize the $1.55 billion upfront cash to support the development of EDG-7500 for hypertrophic cardiomyopathy (HCM). This funding is expected to facilitate the initiation of pivotal phase 3 trials in the fourth quarter of 2026.
- ▪Edgewise Therapeutics has a 'Buy' rating after a $2.65 billion deal with Servier.
- ▪The upfront cash of $1.55 billion will fully fund the development of EDG-7500.
- ▪The company aims to initiate pivotal phase 3 trials for EDG-7500 in Q4 2026.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4912227-edgewise-stock-buy-on-muscular-dystrophy-program-sale-and-edg-7500-advancement"},"author":{"@type":"Person","name":"Terry…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
